A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: JR-131
- Registration Number
- NCT02912533
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Brief Summary
The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients being treated with erythropoiesis stimulating agent.
Read More
Exclusion Criteria
- Patients having complication or history of a cardiovascular / lung / brain infarction.
- Patients having a pronounced hemorrhagic lesion.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description JR-131 JR-131 -
- Primary Outcome Measures
Name Time Method Measure adverse events 52 weeks
- Secondary Outcome Measures
Name Time Method Hemoglobin level 52 weeks